TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33443609
Drug: Testosterone treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone treatment (TT + RT)
Study: 35977107
Drug: High calcium
Normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High calcium meal (CAL; 1000 mg)
Study: 35977107
Drug: Isocaloric low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric low calcium meal (CON; <10 mg)
Study: 33454584
Drug: Ozanimod 0.92
Normalized name: ozanimod 0.92 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozanimod 0.92 mg
Study: 33992274
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy group (B)
Study: 35580836
Drug: Abbreviated dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abbreviated dual antiplatelet therapy (DAPT)
Study: 35580836
Drug: Standard dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dual antiplatelet therapy (DAPT)
Study: 33076878
Drug: Biokesum® (Persicaria
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biokesum® (Persicaria minor extract), 250 mg/capsule, twice daily for 6 months
Study: 34551124
Drug: 300 IR
Normalized name: ORALAIR 300 IR TAB,SL PKT 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 IR HDM tablet (sublingual allergen immunotherapy)
Study: 34280646
Drug: Conventional strains
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional strains (CONV; strains B and C: ADG0‐48 > 60 g/d)
Study: 33805664
Drug: Psychoeducational group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducational group intervention (12 weekly sessions of 90 min)
Study: 37342775
Drug: Non-CPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-CPAP treatment
Study: 35147680
Drug: AmBisome monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmBisome monotherapy (40 mg/kg intravenous liposomal amphotericin B administered in 8 equal doses over 24 days)
Study: 35147680
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (30 mg/kg intravenous AmBisome administered in 6 equal doses over 24 days + 1.4 g oral miltefosine administered in 2 daily doses of 50 mg over 14 days)
Study: 33446902
Drug: 3-5 sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-5 sessions of ALSS therapy
Study: 33446902
Drug: 1-2 sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-2 sessions of ALSS therapy
Study: 33446902
Drug: ≥6 sessions
Approvals — FDA: no, EMA: no, PMDA: no
Description: ≥6 sessions of ALSS therapy
Study: 33446902
Drug: ≤2 sessions
Approvals — FDA: no, EMA: no, PMDA: no
Description: ≤2 sessions of ALSS therapy
Study: 34059932
Drug: pirenzepine 75
Normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pirenzepine 75 mg
Study: 37750406
Drug: vonoprazan 10
Normalized name: vonoprazan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: vonoprazan 10 mg
Study: 34059932
Drug: vonoprazan 10
Normalized name: vonoprazan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: vonoprazan 10 mg plus pirenzepine 75 mg
Study: 34059932
Drug: vonoprazan 10
Normalized name: vonoprazan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: vonoprazan 10 mg alone (control)
Study: 34043794
Drug: Dual hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dual hormone clamp (cortisol and testosterone fixed)
Study: 34704984
Drug: 2g amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2g amoxicillin 1 hour prior to surgery
Study: 33091856
Drug: Cinnamon Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamon Patch (CP)
Study: 34031921
Drug: All implants
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All implants (instrumented and non-instrumented)
Study: 35689170
Drug: Regular conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular conventional medications
Study: 32195950
Drug: Acyclovir and
Normalized name: Acyclovir and hydrocortisone only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir and simulated PDT treatment (control)
Study: 36456740
Drug: Positive pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive pressure therapy (PPT) combined with medications, duration of 8 months.
Study: 36456740
Drug: Medications alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications alone (Control group), n=26.
Study: 36456740
Drug: Positive pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive pressure therapy (PPT) combined with medications.
Study: 36192552
Drug: 35 mg
Normalized name: papain 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg volagidemab
Study: 36192552
Drug: 70 mg
Normalized name: silybin 70 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg volagidemab
Study: 36122501
Drug: Lentil-based meals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lentil-based meals (300 g)
Study: 36122501
Drug: Lentil-based meals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lentil-based meals (600 g)
Study: 36122501
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 g lentils)
Study: 36122501
Drug: Lentil-based meals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lentil-based meals (300 g and 600 g)
Study: 35092891
Drug: TPTD 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPTD 20 μg daily for an average of 6.1 weeks
Study: 35092891
Drug: TPTD 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPTD 20 μg daily
Study: 33818442
Drug: ropivacaine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine (40 mL/0.5%) + dexmedetomidine (1 μg/kg)
Study: 33818442
Drug: ropivacaine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine (40 mL/0.5%) + fentanyl (1 μg/kg)
Study: 33818442
Drug: ropivacaine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine (40 mL/0.5%) + verapamil (2.5 mg)
Study: 33476571
Drug: Ropeginterferon alfa-2b
Normalized name: Ropeginterferon alfa-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ropeginterferon alfa-2b (100 μg subcutaneously every 2 weeks) on top of phlebotomy and low-dose aspirin (100 mg daily)
Study: 33476571
Drug: Phlebotomy (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phlebotomy (300 mL per session to maintain haematocrit <45%) and low-dose aspirin (100 mg daily)
Study: 35686634
Drug: Myo-inositol (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myo-inositol (2000 mg) plus 400 μg folic acid daily from 14-24 gestational weeks
Study: 35686634
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (400 μg of folic acid daily from 14-24 gestational weeks)
Study: 33657259
Drug: 0.03% tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03% tacrolimus ointment (n = 31)
Study: 33657259
Drug: 1% hydrocortisone
Normalized name: HYDROCORTISONE 0.01 g in 1 g TOPICAL OINTMENT [AFASSCO 1% Hydrocortisone]
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1% hydrocortisone acetate ointment (n = 32)
Study: 35100429
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch (NIC) 21 mg, daily
Study: 35100429
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch (PBO)
Study: 33306247
Drug: DAA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAA treatment for <4 weeks in patients with F0-F3 liver fibrosis
Study: 33306247
Drug: DAA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAA treatment for <8 weeks in patients with liver cirrhosis
Study: 32975853
Drug: Acylated ghrelin
Normalized name: Acetyl sulfisoxazole
DrugBank: Acetyl sulfisoxazole (DB14033)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acylated ghrelin infusion
Study: 36461123
Drug: Expectation-optimised video
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expectation-optimised video with patients giving information about their mostly positive therapy outcomes (positive model)
Study: 37468685
Drug: Insulin Degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin Degludec (IDeg)
Study: 38064454
Drug: Optimal drug
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal drug therapy
Study: 33252379
Drug: WHO-recommended second-line
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: WHO-recommended second-line treatment (NRTI group)
Study: 38677468
Drug: Incisional negative
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incisional negative pressure wound therapy (iNPWT)
Study: 33271298
Drug: Hypocaloric high-protein
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypocaloric high-protein diet + fennel (2 capsule/day)
Study: 33271298
Drug: Hypocaloric standardize
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypocaloric standardize diet + fennel (2 capsule/day)
Study: 32371987
Drug: TPN discontinuation
Normalized name: Entex HC Discontinued
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN discontinuation at 100 ml/kg/day
Study: 32371987
Drug: TPN discontinuation
Normalized name: Entex HC Discontinued
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN discontinuation at 140 ml/kg/day
Study: 34159620
Drug: Dexmedetomidine 3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 3.5 µg kg−1 bolus followed by 7 µg kg−1 h−1 infusion (group DEX)
Study: 34159620
Drug: Dexmedetomidine 3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 3.5 µg kg−1 bolus followed by 7 µg kg−1 h−1 infusion combined with vatinoxan 130 µg kg−1 followed by 40 µg kg−1 h−1 infusion (group VAT)
Study: 39213031
Drug: eGFR ≥90
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGFR ≥90 mL/min/1.73 m²
Study: 35234561
Drug: ROSE-010 100
Normalized name: Rose Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: ROSE-010 100 µg
Study: 35234561
Drug: ROSE-010 300
Normalized name: Rose Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: ROSE-010 300 µg
Study: 33475844
Drug: Near-infrared fluorescent
Normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Near-infrared fluorescent cholangiography (NIFC) with preoperative administration of indocyanine green (ICG)
Study: 35508427
Drug: Mandala coloring
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mandala coloring for 30 min during premedication before chemotherapy
Study: 32815423
Drug: Oral semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral semaglutide 7 or 14 mg
Study: 33049709
Drug: Estradiol therapy
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol therapy
Study: 33750239
Drug: Fear-associated human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fear-associated human chemosignals (three doses)
Study: 33893329
Drug: Concurrent bilateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent bilateral stimulation of the ventrolateral PFC (regardless of polarity direction)
Study: 32839029
Drug: Dexmedetomidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.5 μg/kg/h for 30 min before the end of surgery) in groups DD (Dex), ID (Dex), and II(Dex)
Study: 32622074
Drug: Ultrasonic scaling
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonic scaling (US) with usual oral hygiene instructions
Study: 32622074
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with ultrasonic scaling (US)
Study: 36451150
Drug: Intravenous esketamine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous esketamine, administered three times over 6 days (one infusion every other day) as a supplement to conventional antidepressants.
Study: 36451150
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered three times over 6 days (one infusion every other day) as a supplement to conventional antidepressants.
Study: 34169628
Drug: Carbon-assisted Q-switched
Normalized name: Chew Q
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbon-assisted Q-switched Nd: YAG laser treatment
Study: 32201062
Drug: L‐PRF membrane
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐PRF membrane
Study: 33351452
Drug: Single preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single preoperative 500 mg dose of methylprednisolone
Study: 32180528
Drug: Coping with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coping with depression program (individual psychoeducation based on the Neuman systems model, involving cognitive behavioral therapy techniques) administered at six sessions
Study: 33725408
Drug: Low immunosuppression
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low immunosuppression (LI) with tacrolimus monotherapy
Study: 33415860
Drug: Conventional Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Chinese and Western medicine (Control)
Study: 33415860
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between treatment and control groups
Study: 35169165
Drug: GLP-1/GIP combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1/GIP combination
Study: 34788325
Drug: Appropriate empirical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appropriate empirical antibiotic treatment
Study: 35700592
Drug: CoQ10 supplementation
Normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CoQ10 supplementation (120 mg/d)
Study: 37553030
Drug: Risankizumab 150
Normalized name: RISANKIZUMAB 150MG/ML ON-BODY KIT 2.4ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risankizumab 150 mg every 12 weeks
Study: 35679030
Drug: Marine ω-3
Normalized name: marine collagen, soluble
DrugBank: Marine collagen, soluble (DB14246)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marine ω-3 fatty acids, 1 g per day
Study: 33636278
Drug: Enzalutamide monotherapy
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide monotherapy with external beam radiation therapy (RT) for 6 months
Study: 33331182
Drug: Sitafloxacin 100-mg
Normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sitafloxacin 100-mg once-daily for 3-5 days (acute uncomplicated UTI)
Study: 33331182
Drug: Sitafloxacin 100-mg
Normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sitafloxacin 100-mg twice daily for 10-14 days (complicated UTI)
Study: 33331182
Drug: Levofloxacin 500-mg
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500-mg once-daily for 3-5 days (acute uncomplicated UTI)
Study: 33331182
Drug: Levofloxacin 500-mg
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500-mg once-daily for 10-14 days (complicated UTI)
Study: 35995816
Drug: Antithrombin administration
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombin administration to maintain a level of 80-120%
Study: 36418930
Drug: Both smokers
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both smokers and nonsmokers (before and after treatment)
Study: 34637519
Drug: RSV stabilized
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSV stabilized prefusion F subunit vaccine (RSVpreF) with Tdap
Study: 32342642
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) supplementation (5 g/day containing 2 g/day eicosapentaenoic acid and 1 g/day docosahexaenoic acid)
Study: 32342642
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (OO) supplementation (5 g/day)
Study: 33091706
Drug: Methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue (MB) 2 mg/kg intravenous infusion
Study: 32329887
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy plus aromatherapy
Study: 616866158
Drug: Active video
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active video gaming using a motion-controlled video console (Nintendo Wii) for a minimum of 30 minutes a day, 5 days a week, plus weekly Internet-based coaching sessions
Study: 34229729
Drug: Recombinant erythropoietin
Normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant erythropoietin (EPREX) 300 units/Kg or 4000 IU subcutaneous injection three times a day for 5 days, along with Enoxaparin 1 mg/kg SQ daily.
Study: 34229729
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (SOC) and placebo (distilled water) subcutaneous injection three times a day for 5 days.
Study: 32386065
Drug: Brand bupropion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brand bupropion XL 300 mg
Study: 32386065
Drug: Generic bupropion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic bupropion XL 300 mg
Study: 34190167
Drug: Palonosetron-midazolam combination
Normalized name: palonosetron, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron-midazolam combination therapy (group PM)
Study: 34190167
Drug: Palonosetron monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron monotherapy (group P)
Study: 33068301
Drug: Traditional antidiabetic
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional antidiabetic therapy (Control, n = 40)
Study: 35857827
Drug: OP-101 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OP-101 at 4 mg/kg
Study: 35857827
Drug: OP-101 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OP-101 at 4 and 8 mg/kg
Study: 35857827
Drug: Pooled OP-101
Normalized name: OP-101
DrugBank: Acetylcysteine zidrimer (DB16496)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pooled OP-101 treatment arms
Study: 33813267
Drug: Surgeon-delivered exercise
Normalized name: sturgeon, unspecified preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgeon-delivered exercise prescription and activity tracker
Study: 34906747
Drug: Distinct treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distinct treatments in multi-arm trials sharing a control group
Study: 33421558
Drug: Atezolizumab (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (1200 mg intravenously every 3 weeks for 16 cycles)
Study: 33421558
Drug: Atezolizumab (840
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (840 mg intravenously every 3 weeks for 16 cycles)
Study: 32313032
Drug: NMDA stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: NMDA stimulation (250 mg D-cycloserine (DCS))
Study: 35712942
Drug: Oryzanol tablets,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oryzanol tablets, 20 mg orally, 3 times a day for 4 weeks
Study: 32546217
Drug: Whey-protein-infused carbohydrate-loading
Normalized name: whey protein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey-protein-infused carbohydrate-loading drinks pre-operatively and early oral feeding post-operatively.
Study: 34144923
Drug: Amikacin liposome
Normalized name: AMIKACIN LIPOSOME
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin liposome inhalation suspension (ALIS) 590 mg once daily for 12 treatment cycles (96 weeks)
Study: 32822656
Drug: Culprit-only treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culprit-only treatment
Study: 32506539
Drug: Early cord
Normalized name: Bos taurus umbilical cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early cord clamping (CC)
Study: 34167672
Drug: Integral prasugrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integral prasugrel 60-mg loading dose
Study: 32701118
Drug: Vaginal Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal Testosterone Cream (0.5 g daily for 2 weeks, then 0.5 g 3 times a week for 10 weeks)
Study: 36057952
Drug: Generic safinamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic safinamide tablet (test), 100 mg
Study: 36057952
Drug: Brand-name safinamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brand-name safinamide tablet (reference), 100 mg
Study: 34459033
Drug: Melatonin (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (18 mg in 1 ml of corn oil, injected SC)
Study: 34459033
Drug: Control (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (1 ml corn oil only)
Study: 36235788
Drug: DHA/EPA group
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA/EPA group (n = 33) - received six 480 mg capsules containing 576 mg DHA and 284 mg EPA per day for 12 weeks
Study: 33888136
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Lutein and 2 mg Zeaxanthin in safflower oil (Carotenoid group)
Study: 36190391
Drug: Abaloparatide 80
Normalized name: ABALOPARATIDE 80MCG/0.04ML PEN 1.56ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abaloparatide 80 μg daily subcutaneous injections
Study: 34352943
Drug: Ablative CO2
Normalized name: ABL
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ablative CO2 fractional laser (ACFL) treatment
Study: 34983126
Drug: Adjuvant oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant oral therapy with tadalafil 5 mg and L-arginine 2,500 mg
Study: 34983126
Drug: Low-intensity extracorporeal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity extracorporeal shock wave therapy (Li-ESWT) alone
Study: 32088018
Drug: Concurrent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent administration of OPV and RVV